BALYASNY ASSET MANAGEMENT L.P. - CYTOMX THERAPEUTICS INC ownership

CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 77 filers reported holding CYTOMX THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 2.44 and the average weighting 0.0%.

Quarter-by-quarter ownership
BALYASNY ASSET MANAGEMENT L.P. ownership history of CYTOMX THERAPEUTICS INC
ValueSharesWeighting
Q4 2022$55,680
+165.1%
34,800
+135.2%
0.00%
Q3 2022$21,000
-30.0%
14,794
-10.6%
0.00%
Q2 2022$30,000
-53.1%
16,552
+64.5%
0.00%
Q2 2021$64,000
-83.2%
10,059
-39.5%
0.00%
-100.0%
Q2 2018$380,000
-13.6%
16,632
+7.5%
0.00%0.0%
Q1 2018$440,00015,4750.00%
Other shareholders
CYTOMX THERAPEUTICS INC shareholders Q1 2023
NameSharesValueWeighting ↓
BVF INC/IL 5,803,700$25,130,0000.91%
Altium Capital Management LP 663,800$2,874,0000.79%
Rubric Capital Management LP 2,406,449$10,420,0000.49%
RTW INVESTMENTS, LP 6,029,700$26,109,0000.38%
Orbimed Advisors 3,214,509$13,919,0000.18%
TANG CAPITAL MANAGEMENT LLC 152,345$660,0000.13%
PLATINUM INVESTMENT MANAGEMENT LTD 980,085$4,244,0000.12%
Point72 Asset Management, L.P. 6,303,025$27,292,0000.11%
Sender Co & Partners, Inc. 40,720$176,0000.09%
Manteio Capital LLC 15,067$65,0000.08%
View complete list of CYTOMX THERAPEUTICS INC shareholders